Aachen, 30th of April 2024 – Vivalyx, an innovative Organ Vitality Tech startup based in Aachen, announces that it has successfully closed an oversubscribed seed funding round, raising above 5 million EUR. The international investor consortium includes leading European Life Science and Deeptech venture capital firms such as Brightlands Venture Partners, TechVision Fonds, Arve Capital, and the American Deeptech VC Goose Capital, which has already invested in organ preservation solutions prior. Moreover, notable private angel investors have participated in this funding round, including Thomas Ebeling, former CEO of Novartis Pharma, Andrej Henkler, one of the leading European Business Angels for Deeptech investments in the US and Europe, and Springboard Health Angels, one of the largest HealthTech angel groups of central Europe. In addition, previous investors including Angel Invest from Berlin significantly expanded their investment.
Dr. Andreas Schumacher, CEO and co-founder of Vivalyx: “This funding round is a crucial milestone for Vivalyx. It underscores the investors‘ confidence in our products, vision, and team. With the support of our new partners, we are excellently positioned to continue our mission to revolutionize the world of organ transplantation.”
The funding enables Vivalyx to finance the clinical study required for regulatory approval. This crucial step paves the way for the launch of the innovative organ preservation solution, which has the potential to extend the lifespan of donor organs and enhance their vitality. Vivalyx technology aims to significantly increase the number of organs available for transplantation, thus saving and improving the lives of patients worldwide – at significantly lower costs, considerably reduced complexity, and streamlined processes.
Voices from the investors:
Dr. Luc Starmans from Brightlands Venture Partners: “The donor organ shortage presents a tremendous challenge for healthcare systems worldwide. We are excited to work alongside Vivalyx towards developing a novel technology that has the potential to address this challenge by significantly increasing the number of available donor organs.”
Bernhard Kugel from TechVision Fund: „The urgency of Vivalyx’s easy-to-use technology in the organ transplantation field is huge and can revolutionize the industry. We look forward to accompanying the dedicated team and the outstanding technology to improve the quality of donor organs in the next important steps.“
Ashok Rao from Goose Capital: “We are always on the lookout for game-changers in the transplantation sector. Vivalyx’s groundbreaking technology has precisely this potential. I am convinced that Vivalyx will fundamentally change the way we think about and perform organ transplants.”
Christian Schierholz from Arve Capital: “Vivalyx’s innovative technology for the preservation and revitalization of transplant organs presents an unparalleled opportunity to enhance the lives of millions of patients. We are proud to be part of this journey and to support the Vivalyx team in achieving their goals.”
Andrej Henkler from Leblon Capital: “For decades the organ donor market has not seen any significant innovation in organ preservation technology. With its unique technology, Vivalyx brings the long-awaited disruption to this market, presenting a multi-billion-dollar opportunity that is close to market readiness.”
About Vivalyx
Vivalyx GmbH was founded in 2022 in Aachen by Dr. Andreas Schumacher, Dr. Benedict Doorschodt, Prof. Dr. René Tolba, PD Dr. Christian Bleilevens, Prof. Dr. Malte Brettel, and Marius Rosenberg. The Life Science startup has developed an innovative technology for revitalizing donor organs with the goal of enhancing their vitality and thus increasing the number of available organs for life-saving transplants. The Vivalyx team combines medical, medical technology, regulatory, and founding expertise and has already attracted notable investors. For more information, visit here: https://vivalyx.com/
